South Korea · Delayed Price · Currency is KRW Aprogen Biologics Statistics
Total Valuation
KRX:003060 has a market cap or net worth of KRW 33.59 billion. The enterprise value is 279.80 billion.
| Market Cap | 33.59B |
| Enterprise Value | 279.80B |
Important Dates
The next estimated earnings date is Thursday, August 13, 2026.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
KRX:003060 has 13.17 million shares outstanding. The number of shares has decreased by -77.94% in one year.
| Current Share Class | 13.17M |
| Shares Outstanding | 13.17M |
| Shares Change (YoY) | -77.94% |
| Shares Change (QoQ) | +1,377.40% |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 0.42% |
| Float | 5.06M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.43 |
| PB Ratio | 0.12 |
| P/TBV Ratio | 0.17 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.59 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.67, with a Debt / Equity ratio of 0.83.
| Current Ratio | 0.67 |
| Quick Ratio | 0.31 |
| Debt / Equity | 0.83 |
| Debt / EBITDA | n/a |
| Debt / FCF | -5.43 |
| Interest Coverage | -8.85 |
Financial Efficiency
Return on equity (ROE) is -42.75% and return on invested capital (ROIC) is -25.83%.
| Return on Equity (ROE) | -42.75% |
| Return on Assets (ROA) | -12.02% |
| Return on Invested Capital (ROIC) | -25.83% |
| Return on Capital Employed (ROCE) | -33.34% |
| Weighted Average Cost of Capital (WACC) | 4.39% |
| Revenue Per Employee | 199.48M |
| Profits Per Employee | -335.57M |
| Employee Count | 391 |
| Asset Turnover | 0.13 |
| Inventory Turnover | 1.93 |
Taxes
| Income Tax | -1.08B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -75.61% in the last 52 weeks. The beta is -0.22, so KRX:003060's price volatility has been lower than the market average.
| Beta (5Y) | -0.22 |
| 52-Week Price Change | -75.61% |
| 50-Day Moving Average | 3,834.30 |
| 200-Day Moving Average | 7,331.03 |
| Relative Strength Index (RSI) | 34.55 |
| Average Volume (20 Days) | 580,625 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KRX:003060 had revenue of KRW 78.00 billion and -131.21 billion in losses. Loss per share was -10,504.40.
| Revenue | 78.00B |
| Gross Profit | -24.62B |
| Operating Income | -116.82B |
| Pretax Income | -130.89B |
| Net Income | -131.21B |
| EBITDA | -97.74B |
| EBIT | -116.82B |
| Loss Per Share | -10,504.40 |
Balance Sheet
The company has 50.10 billion in cash and 227.15 billion in debt, with a net cash position of -177.05 billion or -13,442.12 per share.
| Cash & Cash Equivalents | 50.10B |
| Total Debt | 227.15B |
| Net Cash | -177.05B |
| Net Cash Per Share | -13,442.12 |
| Equity (Book Value) | 272.85B |
| Book Value Per Share | 15,464.31 |
| Working Capital | -74.70B |
Cash Flow
In the last 12 months, operating cash flow was -36.25 billion and capital expenditures -5.56 billion, giving a free cash flow of -41.82 billion.
| Operating Cash Flow | -36.25B |
| Capital Expenditures | -5.56B |
| Depreciation & Amortization | 19.08B |
| Net Borrowing | 59.74B |
| Free Cash Flow | -41.82B |
| FCF Per Share | -3,174.84 |
Margins
Gross margin is -31.57%, with operating and profit margins of -149.77% and -168.22%.
| Gross Margin | -31.57% |
| Operating Margin | -149.77% |
| Pretax Margin | -167.81% |
| Profit Margin | -168.22% |
| EBITDA Margin | -125.31% |
| EBIT Margin | -149.77% |
| FCF Margin | n/a |
Dividends & Yields
KRX:003060 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 77.94% |
| Shareholder Yield | 77.94% |
| Earnings Yield | -390.64% |
| FCF Yield | -124.50% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 13, 2026. It was a reverse split with a ratio of 0.0666666667.
| Last Split Date | Apr 13, 2026 |
| Split Type | Reverse |
| Split Ratio | 0.0666666667 |
Scores
KRX:003060 has an Altman Z-Score of -1.47 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.47 |
| Piotroski F-Score | 3 |